873 ISM5939, a novel, potent, orally available, selective ENPP1 inhibitor enhances the anti-tumor effects of immune checkpoint inhibitors in syngeneic murine cancer models
Main Authors: | Man Zhang, Jin Liu, Celia Chen, Xin Cheng, Feng Ren, Jianyu Wu, Luoheng Qin, Supriya Bavadekar, Sujata Rao, Alex Zhavoronkov |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
Identification of novel pyrrolopyrimidine and pyrrolopyridine derivatives as potent ENPP1 inhibitors
by: Hee Jin Jeong, et al.
Published: (2022-12-01) -
897-G SR-8541A, a small molecule inhibitor of ENPP1, enhances the effect of immune checkpoint inhibitors in a colorectal cancer model
by: Sunil Sharma, et al.
Published: (2023-11-01) -
Modeling Immune Checkpoint Inhibitor Efficacy in Syngeneic Mouse Tumors in an Ex Vivo Immuno-Oncology Dynamic Environment
by: Daniel T. Doty, et al.
Published: (2020-09-01) -
864 AVA-NP-695, a potent and selective ENPP1 inhibitor, demonstrates strong anti-tumor efficacy as monotherapy and in combination with radiation
by: Sandeep Goyal, et al.
Published: (2023-11-01) -
Development of Novel Ecto-Nucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Tumor Immunotherapy
by: Xiang Wang, et al.
Published: (2022-06-01)